ixazomib,daratumumab
takeda,janssen
['multiple myeloma', 'daratumumab', 'mmsm', 'ixazomib']
elderly frail patients with relapsed/refractory multiple myeloma treated with ixazomib plus daratumumab experienced favorable response rates. #mmsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.